RxDoctor Payments Data

Mary Edwards, APRN

Family · Lexington, KYNPI 1154624492

Payments from drug & device makers

$2,994in general payments, 2019–2025

Across 133 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$380
  • Teva Pharmaceuticals USA, Inc.$307
  • Esperion Therapeutics, Inc.$254
  • Vanda Pharmaceuticals Inc.$238
  • Axsome Therapeutics, Inc.$163
  • Biohaven Pharmaceutical Holding Company Ltd.$156
  • plus $1K from 37 others

What the payments were for

  • Food & beverage$2,994100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,994 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$80,750
Medicare patients
304
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban243$70,923
AustedoDeutetrabenazine12$36,543
Lagevrio (Eua)Molnupiravir30$29,594
OzempicSemaglutide19$22,344
GemtesaVibegron81$21,708
XareltoRivaroxaban72$18,546
TradjentaLinagliptin54$14,158
Potassium Chloride190$9,756
Levothyroxine Sodium563$8,682
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$7,484
LinzessLinaclotide12$6,602
Spiriva HandihalerTiotropium Bromide11$5,980
Mirtazapine181$5,587
Divalproex Sodium139$5,182
JardianceEmpagliflozin13$5,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$70,923243 claims
Teva Pharmaceuticals USA, Inc.Austedo$307$36,54312 claims
MerckLagevrio (Eua), Januvia$34$33,62645 claims
Novo NordiskOzempic$133$22,34419 claims
Sumitomo Pharma America, Inc.Gemtesa$80$21,70881 claims
Boehringer IngelheimTradjenta, Jardiance$13$19,32267 claims
Johnson & JohnsonXarelto$16$18,54672 claims
GSKTrelegy Ellipta$17$7,48414 claims
AbbVieLinzess$380$6,60212 claims
Astellas Pharma US IncMyrbetriq$17$3,42311 claims
Lilly USA, LLCTrulicity$15$3,13912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →